
Sign up to save your podcasts
Or


What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits, his early work with rhodopsin, and the impact of crystallography and structural work. He also shares how he got started with molecular biology training, as well as his thoughts on the state-of-the art for both biologics and small molecules in drug discovery.
LINKS:
Rockefeller University: https://www.rockefeller.edu
GlaxoSmithKline: https://www.gsk.com/en-gb/
By Cambridge Healthtech Institute4.8
2525 ratings
What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits, his early work with rhodopsin, and the impact of crystallography and structural work. He also shares how he got started with molecular biology training, as well as his thoughts on the state-of-the art for both biologics and small molecules in drug discovery.
LINKS:
Rockefeller University: https://www.rockefeller.edu
GlaxoSmithKline: https://www.gsk.com/en-gb/

43,831 Listeners

32,011 Listeners

30,711 Listeners

1,834 Listeners

112,426 Listeners

125 Listeners

9,530 Listeners

320 Listeners

6,094 Listeners

6,444 Listeners

6,394 Listeners

34 Listeners

5,520 Listeners

18 Listeners

13 Listeners